NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Call of Duty 2022 Title Has Apparently Been Leaked

Call of DutyPhoto courtesy of ActivisionThe Call of Duty franchise is notoriously bad at containing leaks. Call of Duty 2022 will apparently be called Call of Duty: Modern Warfare II.Tom Henderson, a writer at IGN, confirmed the title of next year's installment on Saturday, Oct. 9. Henderson also added that the game's artwork is reportedly very well done. His confirmation corroborates a leak last month suggesting that CoD 2022 will be a sequel to 2019's Modern Warfare. No other information came from the previous leak, as much is likely still